| "The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one." | ( Chou, TC; Fowler, NO; Hanenson, IB; Holmes, JC; McCall, D, 1976) |
| "Tachycardia and arrhythmias began approximately 20 seconds after antigen administration and were accompanied, but not preceded, by respiratory and pressor changes." | ( Capurro, N; Levi, R, 1975) |
| "Twenty-four patients with ventricular arrhythmias were treated with oral mexiletine for periods of from one to 16 months (total 10." | ( Julian, DG; Prescott, LF; Talbot, RG, 1976) |
| "Postoperative treatment of ventricular arrhythmia with MSC is a promising procedure and merits further clinical and experimental investigation." | ( Janota, M; Málek, P; Vrána, M; Vránová, Z, 1976) |
| "Out of the 28 severe arrhythmias studied, it was the ventricular extrasystoles which benefited most from treatment (79% completely successful, while there was a lesser degree of success in treating the ventricular tachycardias (35% completely successful, 30% partially successful)." | ( Bellanger, P; Desoutter, P; Motté, G; Vogel, M; Welti, JJ, 1976) |
| "In the treatment of extrasystole, the arrhythmia was eliminated or reduced by 75% in 15 of 23 patients." | ( Grewe, N; Stauch, M, 1977) |
| "The patients were monitored with an arrhythmia counter and the plasma levels of disopyramide measured throughout the treatment period." | ( Besse, P; Page, A; Pic, A, 1979) |
| "In cases with recurring tachyarrhythmias, the drug was also effective in repetitive administration." | ( Chu, D; Cocco, G; Strozzi, C, 1979) |
| "The treatment of arrhythmias in the elderly is as successful and rewarding as in younger patients." | ( Berman, ND, 1979) |
| "Hospital admissions for arrhythmias were reduced from 34 the year before treatment to none the year after." | ( Eydt, JN; Leak, D, 1979) |
| "The absence of arrhythmia in cats was not due to persistent myocardial depressant effects of anaesthesia administered during surgery." | ( Beasley, AB; Kelliher, GJ; Reynolds, RD; Ritchie, DM; Roberts, J, 1979) |
| "Postoperatively, 25 patients developed arrhythmia (29 percent), giving rise to hemodynamic deterioration necessitating aggressive treatment." | ( Adebo, OA; Singh, AK, 1979) |
| "Furthermore dangerous arrhythmias are reported in 1600 cases treated with floating catheters." | ( Enenkel, W; Jobst, C; Kiss, E; Mayer, B; Nobis, H; Pollak, H; Prachar, H; Spiel, R, 1977) |
| "Hypokalemic paralysis and/or arrhythmia must be treated cautiously and replacement therapy given slowly." | ( Shires, RS, 1978) |
| "A higher incidnece of arrhythmias was seen in younger patients in close relation to administration of atropine, but the overall incidence during anesthesia was identical in atropine groups and the control groups." | ( Andersen, JR; Eikard, B, 1977) |
| "The incidence of other arrhythmias was significantly less in the aprindine group compared with the untreated group (P less than 0." | ( Hugenholtz, PG; Remme, WJ; Verdouw, PD, 1977) |
| "Causes, risks and treatment of cardiac arrhythmias are discussed with special reference to extrasystoles developing during anaesthesia." | ( Siepmann, HP, 1977) |
| "The incidences of arrhythmias, heart failure and systolic blood pressure below 70 mm Hg, as well as the mortality rate, were compared with those for another group of 600 myocardial infarction patients who were not given this treatment." | ( Löbel, H; Machtey, I; Nissimov, MR; Syrkis, I, 1976) |
| "Three of four patients with atrial arrhythmias showed improvement during lithium therapy." | ( Hultgren, H; Kao, J; Schroeder, JS; Tilkian, AG, 1976) |
| "Accordingly, 18 patients with tachyarrhythmias were treated with intravenous diphenidol in doses of 0." | ( Horgan, JH; Proctor, JD; ul-Hassan, Z; Wasserman, AJ, 1975) |
| "For the latter ventricular arrhythmias, DPH is usually considered only after other antiarrhythmic drug therapy has failed." | ( Hoffman, BF; Rosen, MR; Wit, AL, 1975) |
| "To treat patients with ventricular arrhythmias properly, one must characterize the arrhythmia, define the underlying heart disease and look for and treat reversible causes." | ( Glantz, SA; Harrison, DC; Winkle, RA, 1975) |
| "Supraventricular arrhythmias complicating acute illnesses were treated with intravenously administered practolol, a cardioselective beta adrenergic blocking agent." | ( Conn, RD; Pribble, AH, 1975) |
| "Results obtained in the treatment of arrhythmia due to electrical instability following angina and of angina following arrhythmia are also described." | ( Disertori, M; Furlanello, F; Lanzetta, T; Piccolo, E; Trevi, GP, 1975) |
| "The antiarrhythmia effectiveness of the treatment is shown by the excellent results obtained in sinus tachycardia, supraventricular paroxysmal tachycardia, high frequency atrial fibrillations and even in a patient with WPW syndrome and supraventricular paroxysmal tachycardia and in one of the 5 patients with ventricular tachycardia." | ( Amoroso, A, 1975) |
| "Quinidine gluconate was used to treat arrhythmia induced with maximal exercise testing." | ( Fisher, L; Gey, GO; Levy, RH; Pettet, G, 1975) |
| "The incidence of arrhythmias increased with the concentration of noradrenaline applied and the dose of tricyclic drug administered." | ( Barth, N; Manns, M; Muscholl, E, 1975) |
| "Attacks of cardiac arrhythmias, thought to be due to adriamycin treatment, were probably related to thrombi in the coronary arteries as a result of disseminated intravascular coagulation." | ( Ali, SS; Löffler, H; Lück, R, 1975) |
| "Risk factors for arrhythmia recurrence despite amiodarone therapy were low left ventricular ejection fraction, inducible ventricular tachycardia by programmed electrical stimulation or persisting ventricular tachycardia on Holter monitoring, and cardiac arrest before the institution of amiodarone therapy." | ( Burckhardt, D, 1992) |
| "Patients whose arrhythmia was inducible by programmed electrical stimulation were assigned to treatment with electrophysiologically guided drug therapy based on serial testing (61 patients) or with metoprolol (54 patients)." | ( Andresen, D; Bach, P; Haberl, R; Hoffmann, E; Oeff, M; Steinbeck, G; von Leitner, ER, 1992) |
| "The incidence of symptomatic arrhythmia and sudden death combined was virtually the same in the two groups with inducible arrhythmia after two years of observation (electrophysiologically guided therapy vs." | ( Andresen, D; Bach, P; Haberl, R; Hoffmann, E; Oeff, M; Steinbeck, G; von Leitner, ER, 1992) |
| "Ventricular arrhythmias were analysed in 38 patients with Stages I-IIB heart failure from 24-hour Holter monitoring data obtained before and after digoxin therapy by comparing with the concentrations of catecholamines." | ( Belenkov, IuN; Gabrusenko, SA; Khodzhakuliev, BG; Masenko, VP; Naumov, VG, 1992) |
| "Larger doses of BAY K 8644 produced arrhythmias only in 12 months old rats, which was not totally abolished by nitroglycerine pretreatment." | ( Khatter, JC; Navaratnam, S, 1992) |
| "For the treatment of these arrhythmias, lidocaine was injected and continuous infusion was started." | ( Ida, K; Inoue, M; Katoh, S; Kondoh, M; Okuda, J; Tatsukawa, H; Terashima, S, 1992) |
| "The incidence of conversion arrhythmias was similar in both treatment groups (adenosine 57%, verapamil 50%, p = NS)." | ( Hood, MA; Smith, WM, 1992) |
| "Dramatic reductions of ventricular arrhythmias were noted during the first 72 hours of the therapy." | ( Chou, R; Desai, B; Ferrick, KJ; Fisher, JD; Kim, SG; Mannino, MM; Roth, JA; Roth, S, 1992) |
| "Suppression of inducible arrhythmias was observed at weeks 1,3-7, and 8 in the amiodarone-treated dogs, whereas no suppression occurred in the placebo-treated group." | ( Abdollah, H; Brennan, FJ; Brien, JF, 1990) |
| "It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracardiac, which are dependent upon dosage and duration of treatment." | ( Puech, P, 1991) |
| "As the arrhythmia did not respond to any kind of therapy, amiodarone treatment was started, which the patient received in a maintenance dose of 600-400 mg/day for 4 years." | ( Fazekas, T; Korom, I; Mágori, A; Pogátsa, G; Ungi, I, 1991) |
| "The incidence of life-threatening arrhythmias in patients with heart failure may be reduced by eliminating facilitating factors like electrolyte disturbances, altered autonomic tone and raised intracardiac pressure rather than by antiarrhythmic medical treatment itself." | ( Bertel, O, 1992) |
| "Ventricular arrhythmias, consistently present during both tests on those administered placebo, were dramatically reduced by nitroglycerin in all 20 patients." | ( Bonetti, F; Chierchia, SL; Cianflone, D; Mailhac, A; Margonato, A; Vicedomini, G, 1991) |
| "The ouabain threshold to induce cardiac arrhythmias in urethane-anaesthetized guinea-pigs was not modified by the administration of either dazmegrel, 4 mg/kg i." | ( Barrigón, S; Salinas, P, 1991) |
| "The interim results of the Cardiac Arrhythmia Suppression Trial requires physicians to use a higher threshold for employing antiarrhythmic agents in the treatment of benign or potentially lethal ventricular arrhythmias." | ( Goin, JE; Morganroth, J, 1991) |
| "There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide." | ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| "The treatment of atrial arrhythmias remains traditional: reduction by drugs or electrotherapy and prevention of recurrences, or simply slowing the ventricular response." | ( Drieu, L; Motté, G; Slama, M, 1990) |
| "Respiratory sinus arrhythmias are quantified following atropine sulfate administration and the resulting vagolytic blockade is used as a pharmacologic challenge technique." | ( Dellinger, JA, 1991) |
| "Treatment requiring arrhythmias in the allopurinol group was 6." | ( Rashid, MA; William-Olsson, G, 1991) |
| "Benign arrhythmias occur in the setting of structurally normal hearts and do not require therapy unless associated with debilitating symptoms." | ( Anderson, JL, 1990) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) has led to serious reconsideration of both the benefit-risk ratio of antiarrhythmic drug therapy and the appropriate therapeutic approach to various cardiac arrhythmias." | ( Anderson, JL, 1990) |
| "The risk of arrhythmia, aggravated by many inotropic therapies, constitutes the major danger to ischemic heart failure; amiodarone, betablockers and preventive nitrate therapy are the most effective and least dangerous antiarrhythmics." | ( Broustet, JP; Douard, H; Koch, M; Massière, JP; Oysel, N, 1990) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) is a randomized, placebo-controlled, double-blind, international, multicenter clinical trial to determine whether suppression of ventricular arrhythmias after myocardial infarction with long-term antiarrhythmic drug treatment will reduce arrhythmic death." | ( Bigger, JT, 1990) |
| "To determine whether arrhythmia suppression could be attributed to beta-blockade, racemic propranolol was then administered in dosages producing the same or greater depression of exercise heart rate." | ( Barbey, JT; Koshakji, RP; Lineberry, MD; Murray, KT; Reilly, C; Roden, DM; Siddoway, LA; Wood, AJ; Woosley, RL, 1990) |
| "Tachyarrhythmias requiring drug therapy were recorded in 32% of the patients in the magnesium group and in 45% of the placebo group." | ( Behar, S; Hod, H; Kaplinsky, E; Marks, N; Rabinowitz, B; Shechter, M, 1990) |
| "Ventricular arrhythmias were studied in isolated rat hearts subjected to regional ischaemia and reperfusion without or with simultaneous treatment with nicergoline (0." | ( Bril, A; Man, RY; Maupoil, V; Opie, LH; Rochette, L; Verry, A, 1990) |
| "In the treatment of cardiac arrhythmias of varying genesis, an "observational study" in 1,160 patients showed that a high-dose oral magnesium preparation (Magnesium-Diasporal N 300 Granulat) was effective." | ( Holzgartner, H; Maier, E; Vierling, W, 1990) |
| "We compared arrhythmias occurrence in the course of 104 episodes of chest pain with ST elevation during which short acting nitrate was not administered (group I) and 114 episodes with administration of 2." | ( Bultas, J; Karetová, D, 1990) |
| "DESIGN - Ventricular arrhythmias were studied in isolated rat hearts (n = 8-15 per experiment) subjected to regional ischaemia and treated with various free radical scavengers and spin trap agents." | ( Coetzee, WA; Dennis, SC; Opie, LH; Owen, P; Saman, S, 1990) |
| "The incidence of arrhythmias necessitating treatment was greater in group B (37%) than in group A (15%)." | ( Afonso, JS; Carvalho, E; Fernandes, JS; Halpern, MJ; Linder, J; Pereira, D; Pereira, JN; Pereira, TG; Rabaçal, C, 1990) |
| "The incidence of ventricular arrhythmias necessitating treatment was reduced by more than half in the group receiving magnesium sulphate." | ( Barnett, DB; Bing, RF; Heagerty, AM; Smith, LF, 1986) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | ( , 1989) |
| "One patient had greater arrhythmia suppression when NAPA and procainamide were combined than when either was administered alone." | ( Funck-Brentano, C; Light, RT; Lineberry, MD; Roden, DM; Woosley, RL; Wright, GM, 1989) |
| "Many of the arrhythmias other than ventricular fibrillation had little hemodynamic consequence and did not require treatment." | ( Linnik, W; Ramos, R; Tintinalli, JE, 1989) |
| "Concerning the frequency of "severe" arrhythmia, there was no statistical difference between the two treatment groups on D7 (p = 0." | ( Blondeau, M; Brunet, M; Fedorowsky, A; Fournier, C; Gensous, D; Kindermans, M; Tournadre, P, 1989) |
| "Cases of angina, infarction, and atrial arrhythmia have been reported during treatment with cisplatin." | ( Alciato, P; Cantone, PA; Fico, D; Gagliardini, R; Petrella, V, 1989) |
| "The severity of these occlusion-induced arrhythmias was exacerbated by pretreatment intravenously with quazodine, IBMX, dibutyryl cyclic AMP and dibutyryl cyclic GMP." | ( Kane, KA; Morcillo-Sanchez, EJ; Parratt, JR; Rodger, IW; Shahid, M, 1985) |
| "The incidence of arrhythmias needing treatment was more than halved (from 47% in the placebo group to 21% in the Mg group; p = 0." | ( Rasmussen, HS, 1989) |
| "In 29 patients with cardiac arrhythmias, refractory periods (RP) of the atrium, atrioventricular node and ventricle were defined before and after intravenous administration of cordarone in a dose of 5 mg/kg body weight." | ( Grishkin, IuN, 1989) |
| "To investigate circadian variation of cardiac arrhythmias ambulatory electrocardiogram monitoring was carried out before and after one week's treatment with a long acting beta-adrenoceptor blocker, nadolol, in 26 patients who presented with symptoms attributable to arrhythmias." | ( Mir, MA, 1986) |
| "During follow-up study, arrhythmia recurred in 1 (17%) of 6 patients whose ventricular tachycardia was noninducible with oral sotalol and in 8 (44%) of 18 with inducible tachycardia but who were continued on oral sotalol therapy." | ( Ellis, T; Lebsack, C; Mead, RH; Ruder, MA; Smith, NA; Winkle, RA, 1989) |
| "We report on a case of cardiac arrhythmia during low dosage therapy of post-herpetic neuralgia with Carbamazepine and Amitriptyline in a patient with chronic renal rejection and cirrhosis." | ( Arisi, L; Paganelli, E, 1988) |
| "Thus tricyclic-induced ventricular arrhythmias usually do not respond well to therapy with standard Class I antiarrhythmic drugs that also have the same direct local anesthetic action and may potentiate the adverse effects of tricyclic antidepressants." | ( Jhamandas, V; Sasyniuk, BI; Valois, M, 1986) |
| "The tachyarrhythmias which were treated were paroxysmal supraventricular tachycardia (21 patients), paroxysmal atrial fibrillation (six patients), and paroxysmal ventricular tachycardia (13 patients)." | ( Bauernfeind, RA; Bauman, JL; Gallastegui, J; Hoff, J; Strasberg, B; Swiryn, S; Welch, WJ, 1986) |
| "While treatment of ventricular arrhythmias is completely justifiable for patients with symptoms, their use to prevent sudden cardiac death has not yet been established." | ( Morganroth, J; Nestico, PF, 1987) |
| "The risk of ventricular arrhythmia is perhaps not negligible when hypokalaemia occurs in certain patients with coronary disease or left ventricular hypertrophy who are under digitalis therapy." | ( Delgado, A; Hannedouche, T, 1988) |
| "Intractable ventricular arrhythmias occurred after five days of oral treatment in one patient (group 1) who had poor left ventricular function, hepatic impairment, and toxic concentrations of drugs at the time of death." | ( Campbell, TJ; Gavaghan, TP; Kelly, RP; Koegh, AM; Morgan, JJ; Thorburn, C, 1988) |
| "Furthermore, using an arrhythmia score analysis, combination therapy was shown to offer significantly greater protection than allopurinol alone." | ( Crome, R; Manning, AS, 1988) |
| "Among arrhythmias, only ventricular extrasystoles (which are frequent and most often occur in pairs or salvos or are polymorphous) tachycardia and ventricular fibrillation may be considered as true complications of mitral valve prolapse and should be treated initially with beta-blockers." | ( Bensaid, J, 1985) |
| "Reperfusion arrhythmias were documented in 16 of 20 successfully recanalized patients who received lidocaine and in 15 of 21 successfully recanalized patients without lidocaine treatment." | ( Jannasch, B; Kuck, KH; Mathey, DG; Schlüter, M; Schofer, J, 1985) |
| "Problems of increased ventricular arrhythmias and diarrhea were noted after therapy was begun." | ( Rubin, SA; Tabak, L, 1985) |
| "The incidence of arrhythmias requiring treatment during the initial week of hospitalization was registered." | ( Balslev, S; McNair, P; Nørregård, P; Rasmussen, HS; Suenson, M, 1987) |
| "Two patients developed aggravation of arrhythmia during inpatient therapy." | ( Asinger, RW; Granrud, GA; Hodges, M; Salerno, DM; Sharkey, PJ, 1987) |
| "Postoperative supraventricular arrhythmias (both treated and untreated) were more frequent after crystalloid cardioplegia (crystalloid, 63%; blood, 40%; diltiazem, 47%; p less than 0." | ( Christakis, GT; Ivanov, J; Khan, N; Madonik, M; Mickle, DA; Mullen, JC; Teoh, KH; Weisel, RD, 1987) |
| "In patients with ventricular arrhythmias refractory to other antiarrhythmic agents, propafenone 450 to 1200 mg/day suppressed arrhythmias in 63% of patients (in long term therapy 66%)." | ( Brogden, RN; Harron, DW, 1987) |
| "Serious arrhythmias (ventricular or supraventricular tachycardia) were noted in all groups, but the incidence was significantly higher in the group of rats given diazepam pretreatment than in the other three groups." | ( Denson, DD; Forsberg, T; Gregg, RV; Sehlhorst, CS; Stuebing, RC; Turner, PA, 1988) |
| "We correlated the induction of these arrhythmias with the values of refractory period, conduction velocity, and wavelength during control and during administration of several drugs." | ( Allessie, MA; Bonke, FI; Lammers, WJ; Rensma, PL; Schalij, MJ, 1988) |
| "Frequent and complex ventricular arrhythmias were more common in patients with a history of long-term digoxin therapy or congestive heart failure." | ( Hirsch, IA; Keats, AS; Slogoff, S; Tomlinson, DL, 1988) |
| "Treatment of functional cardiac arrhythmias with lexotan yielded good response in 50% of cases." | ( Gertsik, LG; Il'icheva, VI; Kukes, VG; Syrkina, EA, 1988) |
| "Acute cardiac arrhythmias have been observed following administration of ACM, but congestive cardiomyopathy has been uncommon." | ( Warrell, RP, 1986) |
| "Holter-detected arrhythmias were reduced in aprindine-treated patients at 3 months (p less than ." | ( Achuff, SC; Baughman, KL; Becker, L; Chandra, NC; Gerstenblith, G; Gottlieb, SH; Heck, C; Henley, S; Humphries, JO; Mellits, ED, 1987) |
| "Amiodarone therapy for cardiac arrhythmias is increasingly being recognized to be associated with pulmonary toxicity." | ( Fishbein, MC; Gang, ES; Kass, RM; Mandel, WJ; Nalos, PC; Peter, T, 1987) |
| "Spontaneous arrhythmias were quantitated by 24-h Holter monitor before and during therapy with indecainide." | ( el-Sherif, N; Fontaine, J; Hariman, R; Macina, G; Stavens, C; Turitto, G; Ursell, S, 1987) |
| "Effective control of arrhythmias during steady-state therapy was achieved in 91 patients (82 percent of the study populations); recurrent arrhythmias or sudden death did not correlate with levels." | ( Falik, R; Flores, BT; Gibson, GA; Josephson, ME; Marchlinski, FE; Shaw, L, 1987) |
| "Treatment of arrhythmias during pregnancy is complicated by insufficient information on the effects of the drug on the fetus or possible alterations of the drug's pharmacodynamics in the mother." | ( Ives, TJ; Lownes, HE, 1987) |
| "In the short term, ventricular arrhythmias were effectively suppressed in 30 (71%) of all 42 patients treated." | ( Garson, A; Moak, JP; Smith, RT, 1987) |
| "Complex arrhythmias (multifocal, early cycle, repetitive, bigeminy, trigeminy or ventricular tachycardia) were present in 5 of 59 of the amiodarone-treated patients (8%) and 20 of 70 placebo-treated patients (28%) (p less than 0." | ( George, T; Hajar, HA; Hockings, BE; Mahrous, F; Taylor, RR, 1987) |
| "Each patient was hospitalized and arrhythmia frequency was quantified during a 48-hour drug-free baseline and during every third day of therapy with increasing incremental sotalol dosages." | ( Bergstrand, RH; Duff, HJ; Roden, DM; Siddoway, LA; Thompson, KA; Wang, T; Woosley, RL, 1986) |
| "The incidence of arrhythmias during graded maximal treadmill exercise in a group of 68 subjects with mild, clinically uncomplicated systemic hypertension treated chronically with diuretics alone for a median of 4." | ( Bause, GS; Fleg, JL; Lakatta, EG, 1987) |
| "In both angina and arrhythmia, when administered twice daily it has been as effective as standard therapeutic agents." | ( Singh, BN; Thoden, WR; Ward, A, 1985) |
| "No consistent pattern of arrhythmias emerged in relation to intravenous amrinone administration." | ( Treadway, G, 1985) |
| "For atrial arrhythmias, procainamide is usually the drug of choice when intravenous therapy is indicated; for oral prophylaxis, quinidine or the sustained-release form of procainamide is more effective than conventional formulation oral procainamide." | ( Anderson, JL, 1985) |
| "The occurrence of complex ventricular arrhythmia in two patients under treatment was not necessarily due to specific effects of the drug but might be explained by the high spontaneous variability of rhythm disorders." | ( Haass, A; Mielke, U; Schmidt, W; Sen, S, 1985) |
| "In general, acute therapy of any tachyarrhythmia associated with hemodynamic collapse consists of DC cardioversion, but skillful use of drug therapy and, occasionally, pacemaking are also highly important in preventing recurrences." | ( Berman, ND, 1986) |
| "Enhanced susceptibility to toxic arrhythmias by digitalis administration has been reported in clinical and experimental myocardial infarction." | ( El-Sherif, N; Gough, WB; Hariman, RJ; Zeiler, RH, 1985) |
| "Small inhomogeneities of arrhythmias between the potassium groups may have been caused by digitalis therapy prior to admission." | ( Nordrehaug, JE, 1985) |
| "Although arrhythmias associated with myocardial infarction are managed primarily with drug therapy, those associated with acute respiratory failure respond best to adequate oxygenation and correction of metabolic and hemodynamic abnormalities." | ( George, RB; Payne, DK, 1985) |
| "The ventricular arrhythmias were completely relieved in 47% of the patients assigned to L and in 60% of those treated with A (p = N." | ( Capucci, A; Magnani, B; Mantovani, B; Maresta, A; Melandri, G, 1985) |
| "Ventricular arrhythmias were observed in 100% of control experiments but in only 25% of experiments after verapamil pretreatment at 0." | ( Hoffman, BF; Legenza, M; Southworth, SR; Temesy-Armos, PN, 1985) |
| "The observed malignant arrhythmias occurred within the first three days of treatment for chronic complex ventricular ectopic activity." | ( Bilgin, Y; Buss, J; Neuss, H; Schlepper, M, 1985) |
| "Nine patients experienced arrhythmias before treatment; 12 patients had posttreatment ectopy." | ( Boyd, JF; Friess, GG; Garcia, JC; Geer, MR, 1985) |
| "Cardiac arrhythmias produced by electrical stimulation of the ventrolateral cardiac sympathetic nerve in dogs were not blocked by the combined administration of propranolol and practolol in amounts that completely blocked cardiac beta-adrenergic receptors." | ( Gillis, RA; Hoekman, T; Pearle, DL, 1974) |
| "Treatment of this arrhythmia should be careful: its benign character often justifies therapeutic abstention." | ( Bouhour, JB; Godin, JF; Horeau, J; Nicolas, G, 1974) |
| "Ventricular arrhythmias were successfully treated with oral lignocaine in four patients." | ( Dickson, DS; Margolin, L; Parkinson, PI, 1970) |
| "Only some anaesthetic ventricular arrhythmias have a rational basis for therapy which is the use of beta-antagonist agents." | ( Opie, LH, 1981) |
| "Symptomatic ventricular arrhythmias require treatment, whereas benign simple ventricular ectopy does not; however, the treatment of asymptomatic high-grade ventricular ectopy remains controversial." | ( Reid, PR; Vlay, SC, 1982) |
| "Our current understanding of human cardiac arrhythmias is primitive and their treatment is largely empirical." | ( Bigger, JT, 1984) |
| "For the treatment of ventricular arrhythmias, beta-adrenoceptor-blocking agents possess antifibrillatory properties, depress diastolic depolarization of ectopic pacemaker activity, reduce electrical instability associated with prolongation of the QT interval, and are specifically effective in suppressing ventricular arrhythmias that are rate (tachycardia) dependent and/or caused by catecholamine-sensitive automaticity." | ( Sung, RJ; Svinarich, JT; Tai, DY, 1984) |
| "Drug therapy of angina pectoris and arrhythmias after myocardial infarction is basically the same as in patients without a history of infarction." | ( Kronik, G, 1984) |
| "During coronary reperfusion, arrhythmias did not differ in control and treated groups." | ( Bolli, R; Fisher, DJ; Miller, RR; Taylor, AA; Young, JB, 1984) |
| "The frequency of ventricular arrhythmia on 24 hour ambulatory electrocardiographic recordings was comparable on recordings obtained in a prestudy screening, during treatment with placebo before administration of NAPA and after treatment with NAPA." | ( Jaillon, P; Kates, RE; Peters, F; Winkle, RA, 1981) |
| "Nineteen patients whose arrhythmias were initially suppressed with acetylprocainamide underwent long-term treatment with this drug." | ( Drayer, DE; Kluger, J; Leech, S; Lloyd, V; Reidenberg, MM, 1981) |
| "Four patients with chronic ventricular arrhythmias, shown to respond over the short term to N-acetylprocainamide (NAPA), were treated for between 3 and 4 yr with NAPA, and 24-hr ambulatory ECGs were obtained monthly to monitor their responses." | ( Atkinson, AJ; Chao, GC; Kushner, W; Lertora, JJ; Nevin, MJ, 1983) |
| "A malignant arrhythmia is one which threatens life and is difficult to predict, prevent or treat." | ( Coumel, P; Leclercq, JF; Slama, R, 1984) |
| "This article discusses arrhythmias in hypertrophic and dilated cardiomyopathy in relation to clinical significance and treatment; when possible, the authors comment on etiology." | ( Goodwin, JF; Krikler, DM; McKenna, WJ, 1984) |
| "Re-entrant supraventricular arrhythmias, such as paroxysmal supraventricular tachycardia, are particularly amenable to treatment with intravenous verapamil." | ( Antman, EM; Braunwald, E; Muller, JE; Stone, PH, 1980) |
| "Ventricular tachyarrhythmias were recurrent in the remaining seven patients, despite withdrawal of the drugs that caused the Q-Tc prolongation, attempted correction of hypokalemia when present and the administration of antiarrhythmic agents to four of the seven." | ( Adgey, AA; Khan, MM; Logan, KR; McComb, JM, 1981) |
| "In addition, less severe ventricular arrhythmias were significantly more common among the placebo-treated patients." | ( Hansteen, V, 1983) |
| "Ventricular arrhythmias determined from 24 hour tapes were more frequent in treated patients though this was not statistically significant." | ( Ambos, HD; Geltman, EM; Jaffe, AS; Roberts, R; Sobel, BE; Strauss, HD; Tiefenbrunn, AJ, 1983) |
| "After evaluation of arrhythmias and treatment with intravenous lidocaine, oral tocainide dosage regimens were based on age, weight, and clinical status." | ( Aronow, WS; Esterbrooks, D; Hee, TT; Hilleman, DE; Mohiuddin, SM; Mooss, AN; Patterson, AJ; Reich, JW; Sketch, MH, 1983) |
| "In 15 patients with ventricular arrhythmias without previous treatment the effectiveness of 2-amino-2',6'-dimethylpropionanilide (tocainide, Xylotocan) and propafenone was compared in a cross-over-trial." | ( Gebhardt, A; Hilpert, P; Schmuderer, R, 1984) |
| "In 4 patients with atrial arrhythmias, circus movement tachycardia developed during oral encainide therapy." | ( Abdollah, H; Brugada, P; Green, M; Wehr, M; Wellens, HJ, 1984) |
| "The incidence of halothane-epinephrine arrhythmias increases after the short-term administration of imipramine, probably because of enhanced noradrenergic transmission." | ( Maze, M; Smith, CM; Spiss, CK, 1984) |
| "under AM therapy the initial arrhythmias were no longer detectable in 41% of the patients." | ( Haddad, R; Konrad, K; Mainitz, M; Mlczoch, J; Probst, P; Scheibelhofer, W; Weber, H; Weissel, M, 1984) |
| "The number of reperfusion arrhythmias was also significantly lower in the treated animals." | ( ten Cate, FJ; Verdouw, PD; Wolffenbuttel, BH, 1983) |
| "Ventricular arrhythmias other than VF are common in acute infarction and, for emotional rather than scientific reasons, often are aggressively treated." | ( Campbell, RW, 1983) |
| "In all, either the arrhythmia was refractory to other drugs, or such therapy was not tolerated." | ( Fenster, PE; Kern, KB, 1983) |
| "In 36 patients with cardiac arrhythmias (predominantly ventricular premature beats), who were on oral aprindine long-term therapy with 50 to 400 mg daily, plasma levels were measured by gas chromatography after 3." | ( Breithardt, G; Michaelis, L; Wirth, KE, 1983) |
| "A case is described of ventricular arrhythmias associated with doxepin and amitriptyline treatment in a patient with preexisting heart disease." | ( Faber, R; Todd, RD, 1983) |
| "Emergency treatment of cardiac arrhythmias was required in 41 newborn and infants aged two days to 9 months (mean 77 days) from July 1977 until September 1981." | ( Eigster, G; Weber, H; Wesselhoeft, H, 1983) |
| "Amiodarone was used to treat cardiac arrhythmias that had been refractory to conventional medical therapy." | ( Gorham, JP; Graham, EL; Greene, HL; Gross, BW; Kudenchuk, PJ; Sears, GK; Trobaugh, GB; Werner, JA, 1983) |
| "Prehospital ventricular arrhythmias present in 7 of 54 treatment patients with recurrent chest pain did not recur following self-injection by a prefilled lidocaine syringe; only one patient who was initially arrhythmia-free had ventricular ectopic beats after lidocaine injection." | ( Capone, RJ; Curwen, E; VanEvery, S; Visco, J, 1984) |
| "Twenty patients with cardiac arrhythmias (ages 37-80 years) were administered 400-800 mg/24 h (5." | ( Zema, MJ, 1984) |
| "Six patients developed ventricular arrhythmias with parenteral administration of vincamine." | ( Castel, JP; Dallocchio, M; Dany, F; Goudoud, JC; Liozon, F; Marsaud, P; Merle, L; Michel, JP, 1980) |
| "The incidence of arrhythmias could be modified by the species of dog used, the anaesthetic employed, the arterial oxygen tension and the administration of several antiarrhythmic drugs." | ( Marshall, RJ; Parratt, JR, 1980) |
| "The stability of the arrhythmia was verified by several control Holter recordings without therapy (average : 3,3 per patient)." | ( Attuel, P; Coumel, P; Leclercq, JF; Milosevic, D; Rosengarten, MD, 1981) |
| "In 4 patients who had supraventricular arrhythmias without having either marked prolongation of max SRT or episodes of syncope, disopyramide was administered orally for a long term, during which these arrhythmias and symptoms disappeared and sinus rate increased." | ( Eno, S; Fujitani, K; Furuta, Y; Mitsuda, H; Miyoshi, A; Satou, H; Tateishi, H; Tsuchioka, Y; Yoshida, M, 1982) |
| "One received digitoxin daily until arrhythmias developed (toxic group), the second sufficient digitoxin to produce an inotropic effect without arrhythmias (nontoxic group), and the third was untreated." | ( Mathew, B; Potter, RD; Williams, JF, 1983) |
| "This may explain the risk of cardiac arrhythmias during digitalis treatment and during severe hypokalemia, and may further explain the increase for myocardial sensitivity for digitalis when hypokalemia is present." | ( Steiness, E, 1981) |
| "For the evaluation of arrhythmias and the assessment of antiarrhythmic therapy prolonged periods of recording, as provided by the Holter system, are needed." | ( Van Durme, JP, 1980) |
| "The pattern of cardiac arrhythmias and their treatment, by propranolol and chlordiazepoxide, during the first 48 hr of alcohol withdrawal has been studied." | ( Jacob, MS; MacLeod, SM; Sellers, EM; Ti, TY; Zilm, DH, 1980) |
| "Malignant ventricular arrhythmias were observed 10 times in the control group and 5 times in the treated group." | ( Brunner, H; Effert, S; Franken, G; Henning, B; Merx, W, 1980) |
| "A satisfactory arrhythmias control (greater than 75 % reduction of premature ventricular complexes per minute as compared to the control period prior to lidocaine administration) was achieved in 19 patients in the mexiletine group and in 16 in the disopyramide treated patients." | ( Condorelli, M; De Luca, N; Rengo, F; Ricciardelli, B; Sacca', L; Trimarco, B; Volpe, M, 1980) |
| "Thirty patients whose arrhythmia did not respond to correction of metabolic disturbances were randomly allocated to receive treatment either with lignocaine or with mexiletine in fixed dosage schedules (15 in each group)." | ( Bury, RW; Hale, G; Higginbotham, M; Mashford, ML; Zuidland, P, 1982) |
| "Complex ventricular arrhythmias, which were present in all 11 patients during the placebo control period, were completely suppressed in eight patients and markedly suppressed in the other three patients during flecainide therapy." | ( Asinger, RW; Conard, GJ; Granrud, G; Haugland, JM; Hodges, M; Krejci, J; Mikell, FL, 1982) |
| "During treatment with phenytoin, the arrhythmia was decreased in all 19 patients and was completely suppressed in 15; the four remaining patients had only uniform VPCs on repeat ambulatory ECG." | ( Blackman, MS; Kavey, RE; Sondheimer, HM, 1982) |
| "In cases with recurring tachyarrhythmias, tiapamil was also effective during successive administrations, the systolic blood pressure was reduced by 10-15%, but severe hypotension was not observed." | ( Bulgarelli, R; Leutenegger, F; Padula, A; Sfrisi, C; Strozzi, C, 1982) |
| "has treated 158 cases of serious cardiac arrhythmias which occurred among 486 interventions." | ( Barletta, GA; Bertini, G; Conti, A; Fattirolli, F; Giuntini, F; Mangialavori, G; Margheri, M; Mazzoni, D; Vannelli, P, 1982) |
| "The treatment group had no cardiac arrhythmias during bronchoscopy while six of the control subjects developed arrhythmias." | ( Fassoulaki, A; Kaniaris, P; Kotsanis, S, 1980) |
| "Three patients had arrhythmias resistant to all conventional antiarrhythmic drugs; in all other patients except one, previous antiarrhythmic drug therapy had to be discontinued because of poor efficacy or unacceptable adverse effects." | ( Somani, P, 1981) |
| "All patients who developed arrhythmias postoperatively had not been pretreated (primed) with oral magnesium chloride and had abnormal QTc intervals both before and after operation." | ( Girdwood, R; Krasner, BS; Smith, H, 1981) |
| "Ventricular arrhythmias should not be treated unless they are serious, because most antiarrhythmic drugs may further impede the AV-conduction." | ( Hansteen, V; Jacobsen, D; Knudsen, K; Reikvam, A; Skuterud, B, 1981) |
| "This arrhythmia was induced by quinidine or disopyramide therapy." | ( Benhorin, J; Corcos, P; Golhman, JM; Keren, A; Stern, S; Tzivoni, D, 1981) |
| "Nine subjects had cardiac dysrhythmias related to treatment, principally those receiving epinephrine and aminophylline." | ( Gibson, G; Josephson, GW; Kennedy, HL; MacKenzie, EJ, 1980) |
| "Ventricular arrhythmias were induced in one third of the dogs following neurochemical administration." | ( Armour, JA; Huang, MH; Wolf, SG, 1994) |
| "The treatment of ventricular arrhythmias in the elderly population is a challenging problem." | ( Akiyama, T; Daubert, JP; Kim, CH, 1994) |
| "The treatment of life-threatening arrhythmias with amiodarone or an implantable cardioverter/defibrillator prolongs patient survival but with significant comorbidity." | ( Arteaga, WJ; Windle, JR, 1995) |
| "The treated arrhythmias were supraventricular in 25 patients (atrial: 10; junctional: 15) and ventricular in 12 patients." | ( Bosser, G; Lethor, JP; Marçon, F; Worms, AM, 1995) |
| "The number of arrhythmias during the first hour of reperfusion was significantly reduced in treated dogs (134 +/- 74 beats/min in control vs." | ( Endo, T; Hayakawa, H; Kiuchi, K; Sato, N, 1993) |
| "Newly induced arrhythmias after encainide administration included unimorphic and polymorphic ventricular tachycardia (VT) as well as VT degenerating rapidly into ventricular fibrillation (VF)." | ( Gehret, JR; Kothstein, T; Lynch, JJ; Stupienski, RF; Wallace, AA, 1993) |
| "The discontinuation of arrhythmia was in favour of a beneficial effect of this treatment which remains to be confirmed." | ( Carel, N; Fetu, D; Fossier, T; Motreff, C, 1994) |
| "In malignant ventricular arrhythmias, further studies are needed to define the limitations of antiarrhythmic drugs in comparison with non-pharmacological treatments, mainly cardioverter/defibrillators." | ( Boriani, G; Capucci, A, 1995) |
| "Patients with cardiac arrhythmias, ischemia, and infarction may benefit from administration of supplemental magnesium." | ( Black, KW; Butterworth, JF; Prielipp, RC; Roberts, PR; Zaloga, GP, 1995) |
| "We treated a patient with arrhythmia during pregnancy with prolonged intravenous administration of lidocaine hydrochloride." | ( Banzai, M; Chimura, T; Hiroi, M; Komiya, H; Sato, S; Tezuka, N, 1995) |
| "Ventricular arrhythmias from a 30 min occlusion of the left coronary artery were assessed in Langendorff perfused isolated hearts removed from rats administered either saline, or endotoxin derived from Escherichia coli (2." | ( Furman, BL; Parratt, JR; Song, W, 1994) |
| "There were no differences in the prearrhythmia or immediate postarrhythmia ventricular heart rate (HR) or systolic (SAP), diastolic (DAP), or mean (MAP) arterial pressures between treated and control groups." | ( Hellyer, PW; Light, GS, 1993) |
| "We investigated prospectively the arrhythmia incidence in 244 patients with AMI receiving alteplase and a double-blind randomized adjunctive therapy with intravenous atenolol, alinidine, or placebo." | ( Ballet, A; Ector, H; Heidbüchel, H; Tack, J; Van de Werf, F; Vanneste, L, 1994) |
| "(a) Clinically documented arrhythmias; (b) use of antiarrhythmic treatments, cardioversion, and insertion of a pacemaker; (c) incidence of all abnormal rhythms during Holter monitoring." | ( Fletcher, S; Roffe, C; Woods, KL, 1994) |
| "In patients with malignant ventricular arrhythmias, antiarrhythmic therapy is known to carry a substantial risk of proarrhythmia." | ( Faber, TS; Hohnloser, S; Just, H; Van de Loo, A; Zehender, M, 1994) |
| "Pharmacological therapy of cardiac arrhythmias continues to evolve, with an increasing shift from class I to class III compounds and beta-blockers." | ( Ahmed, R; Singh, BN, 1994) |
| "The prevalence and mechanism of these arrhythmias during long-term treatment are unknown." | ( Aili, H; Bergfeldt, L; Mathé, AA; Rosenqvist, M, 1993) |
| "Incidence and duration of ventricular arrhythmias in both pretreated and control groups were evaluated on reperfusion." | ( Ravingerová, T; Styk, J; Szekeres, L; Tribulová, N; Ziegelhöffer, A, 1993) |
| "Nine children with arrhythmia (1 automatic atrial tachycardia, 1 premature ventricular construction, and 7 ventricular tachycardia) who started oral treatment using flecainide were studied." | ( Hara, M; Harada, K; Okuni, M; Otuka, M; Sumitomo, N; Ushinohama, H, 1993) |
| "The incidence of arrhythmias, blood pressure elevations, and tachycardia was not increased in patients in AD treatment." | ( Breckwoldt, J; Eyrich, K; Föhring, U; Hansen, D; Syben, R; Zimmermann, J, 1993) |
| "To prevent arrhythmias, bretylium (5 mg/kg) was administered intravenously 10 minutes before catheter manipulation and repeated every 30 minutes throughout the procedure." | ( Gaymes, CH; Gillette, PC; Harold, ME; Schumann, RE; Swindle, MM, 1993) |
| "Therefore, treatment of arrhythmias should be the keystone of management of thioridazine overdosage." | ( Donatini, B; Hall, M; Krupp, P; Le Blaye, I, 1993) |
| "Disappearance of ventricular arrhythmias after treatment was accompanied by increase in activity of of Na,K-adenosine triphosphatase and decrease in plasma level of cAMP regardless of which drug was used." | ( Kosmala, W, 1995) |
| "During a 2-year follow-up, a non-fatal arrhythmia recurred in 1 patient of the metoprolol arm and in 5 patients of the sotalol arm; 1 patient in the latter group died suddenly 2 months after the recurrence, while receiving amiodarone therapy." | ( Antz, M; Cappato, R; Kuck, KH, 1995) |
| "The nature of an arrhythmia and of individual patient factors change over time, requiring a flexible approach to long-term treatment that may be defined only after months or years." | ( Camm, AJ; Sopher, SM, 1996) |
| "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide." | ( Buxton, AE; Heilman, JM; Hopson, JR; Kienzle, MG; Nademanee, K; Rinkenberger, RL, 1996) |
| "Twelve patients had ventricular tachyarrhythmias: seven had successful therapy, and six died, none related to the drug." | ( Fenrich, AL; Friedman, RA; Hulse, JE; Lamberti, JJ; Perry, JC; Triedman, JK, 1996) |
| "Cardiac arrhythmias due to chloral hydrate appear to be responsive to beta blocker therapy." | ( Amitai, Y; Erickson, T; Hryhorczuk, D; Sing, K, 1996) |
| "For some arrhythmias, such as atrial fibrillation, it seems likely that drug therapy will remain an important part of treatment." | ( Roden, DM, 1996) |
| "Occurrence rates of arrhythmias treated with drugs tested for efficacy either by suppression of inducible arrhythmias or by suppression of spontaneous ectopy were higher and equivalent for both testing methods." | ( Lazzara, R, 1996) |
| "The incidence of reperfusion-induced arrhythmias was significantly lower in the treatment group." | ( Koci, G; Podesser, B; Wollenek, G; Wolner, E; Zegner, M; Zwölfer, W, 1996) |
| "This therapy may be long performed for arrhythmias even in patients with circulatory insufficiency and cardiac conduction disturbances caused or redoubled by ethacizin." | ( Bartashevich, VV; Galenko-Iaroshevskiĭ, PA; Kanorskiĭ, SG; Khankoeva, AI; Skibitskiĭ, VV; Uvarov, AV, 1996) |
| "However, the lack of proarrhythmia and the reduction in arrhythmic death support the use of amiodarone in patients for whom antiarrhythmic therapy is indicated." | ( Camm, AJ; Frangin, G; Janse, MJ; Julian, DG; Munoz, A; Schwartz, PJ; Simon, P, 1997) |
| "Doses for arrhythmias and asystole as well as plasma bupivacaine concentrations at arrhythmia onset were dramatically smaller in L-NAME-pretreated rats than in the other two groups." | ( Heavner, JE; Shi, B, 1997) |
| "In untreated hearts, tachyarrhythmias occurred during the reperfusion, and less pronounced during the coronary occlusion itself." | ( Bernauer, W, 1997) |
| "Drugs can cause cardiac arrhythmias in a number of clinical situations, and many of the implicated agents are used to treat non-cardiac conditions." | ( Doig, JC, 1997) |
| "Acute episodes of arrhythmia are managed by bolus administration of Sotahexal [correction of Hexal]." | ( Avdeĭchuk, ED; Bezprozvannyĭ, AB; Chestukhin, VV; Dorofeeva, EIu; Gorshkov, VA; Kesarev, GV; Lazutina, OM; Lyskovtsev, VV; Nesvetov, VN; Radzevich, AE, 1997) |
| "The frequency and severity of arrhythmias were greatly exacerbated in the MCT-treated animals in the second treatment regimen and were accompanied by one, three, and two deaths in the low-, medium-, and high-dose groups, respectively." | ( Campen, MJ; Costa, DL; Watkinson, WP, 1998) |
| "Forty (40) patients with cardiac arrhythmias receiving procainamide (PA) therapy and 24 patients who were receiving other drugs for their cardiac disorders were investigated for class II HLA phenotypes and their DRB1*04 and DQB1*03 subtypes." | ( Adams, LE; Balakrishnan, K; Hess, EV; Malik, S; Mongey, AB; Whitacre, L, 1998) |
| "The following arrhythmias were treated: reentrant supraventricular tachycardia in 388 patients, atrial ectopic tachycardia in 66, junctional ectopic tachycardia in 39, atrial flutter in 21, ventricular premature complexes in 140, ventricular tachycardia in 78, and other arrhythmias in 39 patients." | ( Janousek, J; Paul, T, 1998) |
| "We studied the changes in arrhythmia profile and heart-rate variability, during abrupt withdrawal of carbamazepine and phenytoin treatment in 10 patients with side effects on these drugs." | ( Bergfeldt, L; Ericson, M; Kennebäck, G; Tomson, T, 1997) |
| "However, whether tachyarrhythmias are truly the cause of syncope, and whether treatment of these tachyarrhythmias can prevent recurrent syncope and arrhythmic death, is unknown." | ( Aguinaga, L; Anguera, I; Brugada, J; Matas, M; Mont, L; Valentino, M, 1998) |
| "We observed a sex difference in cardiac arrhythmias associated with administration of erythromycin." | ( Drici, MD; Knollmann, BC; Wang, WX; Woosley, RL, 1998) |
| "He had persistent cardiac arrhythmias and was intolerant of angiotensin-converting enzyme inhibitor therapy." | ( Massin, EK, 1998) |
| "For patients with an ICD, infrequent arrhythmias and a low probability of inappropriate device discharges, no antiarrhythmic therapy is required." | ( Dorian, P; Greene, M; Newman, D, 1998) |
| "Treatment of cardiac arrhythmia by repeated intravenous injections of propranolol (1 mg/kg) or verapamil (1 mg/kg) was effective and prolonged survival time to 91." | ( Diederich, KW; Strubelt, O, 1999) |
| "In the ouabain-induced arrhythmia model of the guinea pig, pretreatment with AH-1058 (0." | ( Dohmoto, H; Hara, Y; Nakaya, H; Sasaki, N; Shoji, M; Takahara, A; Ueda, H; Uneyama, H; Yoshimoto, R, 1999) |
| "Life-threatening arrhythmias of the heart after myocardial infarction or ischemia may be treated quickly and efficiently by the new drug E 047/1." | ( Atlee, JL; Bajic, J; Bosnjak, ZJ; Hogan, Q; Kulier, AH; Novalija, E; Vicenzi, MN; Woehlck, HJ, 1999) |
| "In patients with ventricular arrhythmias and implantable cardioverter defibrillators (ICDs), antiarrhythmic agents are increasingly being used as adjunct therapy to decrease the frequency of ICD discharges." | ( Sager, PT, 2000) |
| "The risk of ventricular arrhythmias is known to increase during hemodialysis (HD) treatment, but the cause of this phenomenon has remained unidentified." | ( Mustonen, JT; Näppi, SE; Pasternack, AI; Saha, HH; Virtanen, VK, 2000) |
| "Typical arrhythmias are torsade de pointes occurring during treatment with K(+)-channel inhibitors (e." | ( Borchard, U; Hafner, D, 2000) |
| "Hypotension and arrhythmias were treated with epinephrine, open-chest massage, and advanced cardiac life support protocols, respectively." | ( Butterworth, J; Deal, DD; Groban, L; James, RL; Vernon, JC, 2001) |
| "The risk of fatal arrhythmia with cisapride was believed to outweigh the benefit for the approved indication, treatment of nocturnal heartburn due to gastroesophageal reflux disease, leading to the drug's discontinuation in the United States." | ( Corken, A; Gallo-Torres, H; Rodriguez, EM; Talarico, L; Wysowski, DK, 2001) |
| "Infarct, arrhythmia, heart rate and coronary artery flow were determined in hearts treated with vehicle, RST extract, Tet, Fan, or verapamil." | ( Chen, CF; Pang, KT; Shan, J; Wang, GY; Wong, TM; Wu, S; Yu, XC, 2001) |
| "It is important to monitor for arrhythmia when hyperthyroidism develops during amiodarone therapy." | ( Hagiwara, N; Kasanuki, H; Matsuda, N; Sato, K; Shiga, T; Shoda, M; Wakaumi, M, 2001) |
| "(1) Arrhythmia scores of ischemic arrhythmia and reperfusion arrhythmia observed in the rats treated with IH 28-day (IH28) and 42-day (IH42), one week (IH28-1W) and two weeks (IH28-2W) after 28-day IH, as well as in those with continued hypoxia 28-day (CH28) and 42-day (CH42), were significantly lower than controls." | ( Zhang, Y; Zhong, N; Zhou, ZN; Zhu, HF, 2000) |
| "Patients with other supraventricular arrhythmias may be treated with adenosine, a calcium channel blocker, or a short-acting beta blocker to disrupt reentrant pathways." | ( Hebbar, AK; Hueston, WJ, 2002) |
| "Patients with bradyarrhythmias were treated with intravenous boluses of atropine and intravenous infusions of isoprenaline." | ( de Silva, CE; de Silva, HJ; Fonseka, MM; Gunatilake, SB; Seneviratne, SL, 2002) |
| "During aconitine-induced arrhythmias the antiarrhythmic effect of DALDA (Tyr-D-Arg-Phe-Lys-NH2) and nociceptin (orphanin FQ) administered intravenously depended on activation of nitric oxide synthase." | ( Krylatov, AV; Lishmanov, YB; Maslov, LN; Solenkova, NV; Stakheev, DL, 2003) |
| "Since malignant tachyarrhythmias cause sudden death in ischemic heart disease, attenuation of NE release by selective H(3)R agonists may represent a new approach in the prevention and treatment of ischemic arrhythmias." | ( Heerdt, PM; Koyama, M; Levi, R, 2003) |
| "Seven of the 21 (33%) presented with a cardiac arrhythmia expected to possibly respond to NaHCO(3) treatment." | ( Calkins, T; Chan, TC; Clark, RF; Stepanski, B; Vilke, GM, 2003) |
| "The exact place of this treatment of cardiac arrhythmias has not yet been clearly defined." | ( BROWN, KW; MORROW, JD; WHITEHEAD, EH, 1964) |
| "Ventricular arrhythmia was not induced by administration of pilsicainide in 55 patients (no-VA group)." | ( Banba, K; Emori, T; Hina, K; Kita, T; Kusano, KF; Matsubara, H; Morita, H; Morita, ST; Nagase, S; Nakamura, K; Nishii, N; Ohe, T; Tani, Y; Watanabe, A, 2003) |
| "Postictal arrhythmia following MES-induced seizures may be blocked by pretreatment with atropine methyl bromide, a peripherally acting parasympatholytic agent." | ( Darbin, O; Naritoku, DK, 2004) |
| "In addition, arrhythmia was produced by the administration of amitriptyline under dark conditions." | ( Kanke, M; Sugiyama, T; Yoshiyama, Y, 2004) |
| "Many patients with cardiac arrhythmias require concomitant therapy with warfarin and amiodarone." | ( Ezra, D; Farfel, Z; Halkin, H; Kurnik, D; Loebstein, R; Olchovsky, D, 2004) |
| "Incidence of arrhythmias during ischemia and reperfusion, including ventricular premature beats and ventricular fibrillation, was significantly decreased in the SQS-pretreated group (P<0." | ( Chen, YZ; He, M; Huang, Q; Lai, ZF; Nishi, K; Shao, Z, 2004) |
| "Asymptomatic patients with inducible arrhythmia underwent electrophysiologic (EP)-guided therapy." | ( Cauchemez, B; Clerc, J; Denjoy, I; Di Fusco, S; Extramiana, F; Guicheney, P; Hermida, JS; Jarry, G; Leenhardt, A; Milliez, P; Rey, JL, 2004) |
| "We assessed its potential to generate cardiac arrhythmias by analysing ECG recordings from clinical studies on intravenously administered levosimendan in heart failure patients." | ( Lehtonen, L; Lilleberg, J; Toivonen, L; Ylönen, V, 2004) |
| "However, for the safe treatment of arrhythmias nearly all presently known blockers lack sufficient selectivity, either within the target family or with respect to other ion channels modulating the cardiac action potential." | ( Englert, HC; Gerlach, U; Heitsch, H; Knieps, S, 2003) |
| "Reperfusion arrhythmias in control preparations had electrophysiological characteristics of activity initiated by afterpotentials; however, arrhythmias with these characteristics were absent in pinacidil-pretreated preparations, and all reperfusion arrhythmias exhibited characteristics of reentry." | ( Ferrier, GR; Howlett, SE, 2005) |
| "In addition, arrhythmias did not occur after administration of another vasoconstrictor (phenylephrine)." | ( Best, SR; Kosloski, LM; Orr, JA; Porter, CB; Smoot, RL; Stachura, CJ; Wacker, MJ, 2006) |
| "Incidence of atrial tachyarrhythmias lasting 5 minutes or longer that prompted therapy by the sixth postoperative day." | ( Bayes, AJ; Burgess, JJ; Connolly, CJ; Exner, DV; Ferland, A; Kidd, WT; Kieser, T; MacAdams, CL; Maitland, A; Mitchell, LB; Prystai, GD; Wyse, DG, 2005) |
| "The immediate treatment of arrhythmias involves correcting hypoxia, electrolyte abnormalities, hypotension and acidosis." | ( Bradberry, SM; Thanacoody, HK; Thomas, SH; Vale, JA; Watt, BE, 2005) |
| "The median time to arrhythmia recurrence in both treatment groups with structural heart disease was 13 days, and the difference between treatments was not significant (P = ." | ( Connolly, S; Kerr, C; Kowey, P; Page, RL; Pritchett, EL; Wilkinson, WE, 2006) |
| "No cardiac arrhythmias were observed, and lidocaine was effective in 76% of the treatments." | ( de Vries, LS; Malingré, MM; Rademaker, CM; Toet, MC; van Kesteren, C; Van Rooij, LG; Ververs, TF, 2006) |
| "We studied whether tachyarrhythmia and/or the drugs used to treat arrhythmias affect risk of fracture." | ( Mosekilde, L; Rejnmark, L; Vestergaard, P, 2007) |
| "Twenty-two patients with a history of arrhythmia undergoing elective knee surgery were randomly assigned to two groups: group M (n = 11), administered with MgSO(4) 40 mg." | ( Kosugi, S; Morisaki, H; Sakuraba, S; Serita, R; Takeda, J; Tanaka, C, 2007) |
| "Doxorubicin may result in arrhythmias both in early and late periods of treatment." | ( Akgul, E; Aksoy, S; Aytemir, K; Barista, I; Kilickap, S; Tekuzman, G, 2007) |
| "Provocation of fatal cardiac arrhythmias has limited the use of inotropic agents as heart failure therapy." | ( Das, B; Sarkar, C, 2007) |
| "A prespecified set of arrhythmias were evaluated by a core laboratory blinded to treatment and outcomes." | ( Belardinelli, L; Braunwald, E; Gersh, BJ; Hedgepeth, CM; Hod, H; McCabe, CH; Molhoek, P; Morrow, DA; Murphy, SA; Scirica, BM; Verheugt, FW, 2007) |
| "Due to potential arrhythmia risk from observed QT prolongation, alternans was assessed in the anesthetized guinea pig after azithromycin or chloroquine alone and after combination treatment at clinically relevant concentrations proposed for the management of malaria." | ( Deng, S; Duncan, JN; Dunne, M; Fossa, AA; Wisialowski, T, 2007) |
| "Both treatments reduced arrhythmia induction from 75% in dTGRs to 17% versus 0% in Sprague-Dawley rats." | ( Dechend, R; Feldt, S; Fischer, R; Gapelyuk, A; Herse, F; Heuser, A; Luft, FC; Markovic, M; Muller, DN; Park, JK; Plehm, R; Qadri, F; Safak, E; Schirdewan, A; Schunck, WH; Schwarz, I; Zacharzowsky, UB, 2008) |
| "Exacerbation of AMIR-related arrhythmia and increased reperfusion-related mortality were observed only in rats treated with DMSF." | ( Kobayashi, T; Ohara, N; Yokota, S, 2008) |
| "Episodes of torsade de pointes arrhythmia during methadone treatment have been reported in patients with other risk factors for arrhythmia, while small prospective studies have reported a small, lasting and stable increase in QTc time." | ( Borchgrevink, PC; Dale, O; Fredheim, OM; Kaasa, S; Moksnes, K, 2008) |
| "The treatment of cardiac arrhythmias has undergone a sea change with the advent of catheter ablative procedures (radiofrequency ablation) and use of implantable cardioverter defibrillator (ICD)." | ( Sharma, S, 2007) |
| "The pretreatment arrhythmia occurrence frequency in these patients was also described." | ( Baumgartner, RA; Cheng, H; Grogan, DR; Hanrahan, JP; Morganroth, J; Wilson, A; Zimetbaum, PJ, 2008) |
| "We present two cases of proarrhythmia after propafenone treatment." | ( Jastrzebski, M, 2008) |
| "The use of amiodarone for total arrhythmia was significantly more effective than prophylactic treatment with magnesium sulphate (p = 0." | ( Ari, H; Demirtas, S; Huysal, K; Ozyazicioglu, A; Selimoglu, O; Tiryakioglu, O; Tiryakioglu, SK, 2009) |
| "Accordingly, severity of arrhythmias (arrhythmia score) and infarct size were lower in hyperoxia-treated groups." | ( Akbari, Z; Bigdeli, MR; Esmailidehaj, M; Hajizadeh, S; Khoshbaten, A; Pourkhalili, K; Tiraihi, T, 2009) |
| "Experimental arrhythmias were induced by the ligation of the left anterior descending coronary artery for 10 min with subsequent reperfusion or by administration of calcium chloride or aconitine at arrhythmogenic doses." | ( Cirule, H; Dambrova, M; Kalvinsh, I; Kuka, J; Liepinsh, E; Veveris, M; Vilskersts, R, 2009) |
| "However, there were significantly more cardiac arrhythmias with DA treatment." | ( Balk, RA; Elpern, E; Grahe, JS; Lateef, O; Patel, GP; Singla, S; Sperry, M, 2010) |
| "These arrhythmias and impaired LV function were significantly inhibited by co-administration of 4-ClDzp (64 microM): arrhythmia scores with diamide+4-ClDzp were 0." | ( Anderson, EJ; Aon, MA; Brown, DA; Frasier, CR; Maloney, AH; O'Rourke, B; Sloan, RC, 2010) |
| "The vulnerability for ventricular arrhythmia during programmed stimulation in estradiol-treated infarcted rats was significantly lower than in vehicle-treated infarcted rats." | ( Chen, CC; Lee, TM; Lin, CC, 2010) |
| "The dose of ouabain required to induce cardiac arrhythmias was much larger in guinea pigs administered with isorhynchophylline." | ( Dong, G; Fu, S; Gan, R; Wang, X; Yang, S; Yu, J, 2011) |
| "To estimate risk of death due to cardiac arrhythmia during methadone maintenance treatment." | ( Batey, R; Bell, J; Butler, B; Lawrance, A; Rubin, G, 2011) |
| "We report a case of cardiac arrhythmia occurring in a Guillain-Barré syndrome (GBS) patient after succinylcholine administration during third endotracheal intubation, on day 13 of illness." | ( Hor, JY, 2010) |
| "Safe pharmacotherapy and prevention of arrhythmia is an urgent problem of modern cardiology." | ( Egorova, EIu; Gromova, OA; Rudakov, KV; Torshin, IIu, 2011) |
| "Various cardiac arrhythmias have been reported during corticosteroid pulse therapy." | ( Aghsaie, A; Darabi, L; Minagar, A; Sahraian, MA; Vasheghani-Farahani, A, 2011) |
| "The incidence of cardiac arrhythmias was not significantly reduced after 6 months of intensive iron removal therapy in the group A subjects." | ( Bolan, CD; Leitman, SF; Rosing, DR; Shizukuda, Y; Tripodi, DJ; Waclawiw, MA; Yau, YY; Zalos, G, 2012) |
| "The ideal treatment for fetal arrhythmias associated with hydrops is not known." | ( Sanghavi, DM, 2013) |
| "Likewise, the severity of arrhythmias was lower in KN-treated hearts." | ( Adameova, A; Carnicka, S; Nemcekova, M; Rajtik, T; Ravingerova, T; Svec, P; Szobi, A, 2012) |
| "However, the occurrence of arrhythmia with conduction disturbance such as second-degree atrioventricular blocks was markedly diminished by pretreatment with atropine, while the occurrence of ventricular extrasystole was augmented by atropine." | ( Ando, K; Ito, K; Kuwahara, M; Ngampongsa, S; Tsubone, H, 2012) |
| "Ventricular arrhythmia requiring ICD therapy." | ( Cheetham, A; George, RS; Kelion, AD; Marshall, A; Mason, M, 2012) |
| "The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test whether the arrhythmia suppression translates into prevention of sudden death, assessed the impact of flecainide and encainide therapy in patients with frequent ventricular ectopics and reduced left ventricular function who had survived an infarction." | ( Apostolakis, S; Breithardt, G; Fabritz, L; Kirchhof, P; Oeff, M; Tebbe, U, 2013) |
| "Tachyarrhythmia persisted in two patients despite combination therapy, and treatment regimen was changed." | ( Akin, A; Alehan, D; Aykan, HH; Karagöz, T; Özer, S; Özkutlu, S, 2013) |
| "Prevention of arrhythmias by administration of magnesium." | ( Kisters, K; Liebscher, DH; Micke, O; Vierling, W; von Ehrlich, B, 2013) |
| "The incidence of arrhythmia requiring treatment, mortality due to arrhythmia, hemodynamics, and arterial blood gas values during surgery were analyzed in these three groups." | ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| "The incidence of arrhythmia requiring treatment was significantly decreased in the AP group compared with that in the NP or SP groups (4." | ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| "To explore the risk of cardiac arrhythmias associated with ondansetron administration in the context of recent recommendations for identification of high-risk individuals." | ( Finkelstein, Y; Freedman, SB; Rumantir, M; Uleryk, E, 2014) |
| "The primary outcome was arrhythmia occurrence temporally associated with the administration of a single, oral ondansetron dose." | ( Finkelstein, Y; Freedman, SB; Rumantir, M; Uleryk, E, 2014) |
| "Primary: No reports describing an arrhythmia associated with single oral ondansetron dose administration were identified." | ( Finkelstein, Y; Freedman, SB; Rumantir, M; Uleryk, E, 2014) |
| "Cardiac arrhythmias are electrical phenomena; thus, sarcolemmal ion channels have long been considered as targets of antiarrhythmic therapy." | ( Rocchetti, M; Zaza, A, 2015) |
| "The previous study showed that the cardiac arrhythmias induced by myocardial ischemia and reperfusion were attenuated by the pretreatment of acupuncture; however, the related mechanism is not understood." | ( Cui, J; Gao, J; Lu, F; Ma, S; Qin, L; Wang, Y; Xin, J; Yu, X; Zhao, Y, 2015) |
| "The sensitivity to triggering of arrhythmia was measured in a separate cohort one day after exposure using intravenously administered aconitine." | ( Cascio, WE; Duvall, R; Farraj, AK; Haykal-Coates, N; Hazari, MS; Higuchi, M; Kovalcik, K; Malik, F; McGee, J; Walsh, L; Winsett, D, 2015) |
| "Cardiac arrhythmias are important causes of infant morbidity, and an occasional cause of infant mortality if undiagnosed and untreated." | ( Aydemir, O; Bas, AY; Celik, IH; Demirel, N; Isik, DU; Kavurt, S; Kibar, AE, 2016) |
| "VF incidence and arrhythmia score were lower and infarcts were 49% smaller in the pinocembrin-treated group than in the control group (p < 0." | ( Arjinajarn, P; Chattipakorn, N; Lungkaphin, A; Palee, S; Pompimon, W; Pongchaidecha, A, 2015) |
| "DZX promoted the incidence of arrhythmias, because all DZX-treated T2DM hearts exhibited ischemia-induced VTs that persisted on reperfusion." | ( Akar, FG; Hu, J; Karam, BS; Motloch, LJ; Xie, C, 2015) |
| "At 7 days post-MI, the arrhythmia score of programmed electric stimulation in the vehicle-treated infarcted rats was higher than that in rats treated with DAPT." | ( Cheng, W; Hu, H; Li, X; Shi, Y; Wang, Y; Xuan, Y; Xue, M; Yan, S; Yang, N; Yin, J, 2016) |
| "The reduction of fatal ventricular arrhythmias through exercise-induced mitochondrial adaptations indicates that mitochondrial therapeutics may be an effective target for the treatment of heart disease." | ( Alleman, RJ; Brown, DA; McClung, JM; Neufer, PD; Patteson, DJ; Ryan, TE; Shaikh, SR; Spangenburg, EE; Tsang, AM, 2016) |
| "HN analogue pretreatment decreased arrhythmia incidence and infarct size, improved cardiac mitochondrial function, and attenuated cardiac dysfunction." | ( Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Kerdphoo, S; Shinlapawittayatorn, K; Thummasorn, S, 2016) |
| "We further show that DM-induced arrhythmias can be successfully treated by inhibiting the IL-1β axis with either IL-1 receptor antagonist or by inhibiting the NLRP3 inflammasome." | ( Alarcón, ML; Bassani, RA; Bonomo, A; Bozza, MT; Brasil, G; Burgos, JI; Carvalho, AB; Casis, O; de Carvalho, ACC; Dutra, FF; Fleischmann, BK; Hochman-Mendez, C; Malan, D; Medei, E; Monnerat, G; Paiva, CN; Sepúlveda, M; Travassos, LH; Vasconcellos, LR; Vila-Petroff, M, 2016) |
| "Cardiac arrhythmias associated with intracellular calcium inhomeostasis are refractory to antiarrhythmic therapy." | ( Chu, YP; Ding, YS; Huang, SH; Huo, Y; Ren, L; Wang, P; Wei, XH; Wu, L; Yang, QM; Yang, W; Yu, SD, 2017) |
| "Noninvasive ablation of cardiac arrhythmia by scanned particle radiotherapy is highly promising, but especially challenging due to cardiac and respiratory motion." | ( Bert, C; Constantinescu, AM; Durante, M; Eichhorn, A; Graeff, C; Kaderka, R; Lehmann, HI; Lugenbiel, P; Packer, DL; Prall, M; Richter, D; Takami, M; Thomas, D, 2017) |
| "We extracted incidence of postoperative arrhythmias, termination following magnesium administration and secondary outcomes (including mortality, length of stay, hemodynamic parameters, biochemistry)." | ( Bellomo, R; Fairley, JL; Glassford, NJ; Zhang, L, 2017) |
| "Purkinje fiber-mediated arrhythmias in the setting of acute myocardial infarction are poorly responsive to conventional antiarrhythmic therapy, increases overall mortality and often requires radiofrequency ablation (RFA) for control." | ( Kamath, P; Kamath, RL; Marla, J; Pai, N; Patel, K; Prabhu, MA; Rai, MK, 2018) |
| "Efficacy in treating the clinical arrhythmia was assessed as complete, partial or failure." | ( Celermajer, DS; Cordina, RL; McGuire, MA; Moore, BM, 2019) |
| "The pharmacologic treatment of arrhythmias has seen little advance over the past few years." | ( Kerin, NZ, 2018) |
| "The reduction of ventricular arrhythmias, atrioventricular block, and lethality and serum levels of creatine kinase produced by treatment with orlistat in animal model of cardiac isquemia/reperfusion injury suggest that ORL could be used as an efficient cardioprotective therapeutic strategy to attenuate myocardial damage related to acute myocardial infarction." | ( Araújo, EA; Caricati-Neto, A; Errante, PR; Ferraz, RRN; Ferreira, RM; Govato, TCP; Luna-Filho, B; Menezes-Rodrigues, FS; Oliveira-Júnior, IS; Paula, L; Reis, MDCM; Taha, MO; Tavares, JGP; Tikazawa, EH, 2018) |
| "Susceptibility to cardiac ventricular arrhythmias was significantly reduced in propionate-treated angiotensin II-infused wild-type NMRI mice." | ( Avery, EG; Balogh, A; Bartolomaeus, H; Dechend, R; Eckardt, KU; Fielitz, J; Forslund, SK; Gollasch, M; Grandoch, M; Haase, N; Hering, L; Höges, S; Homann, S; Kempa, S; Kozhakhmetov, S; Kräker, K; Krannich, A; Kusche-Vihrog, K; Kushugulova, A; Maase, M; Markó, L; Müller, DN; Rump, LC; Stegbauer, J; Tsvetkov, D; Wilck, N; Wundersitz, S; Yakoub, M; Zhumadilov, Z, 2019) |
| "There was no evidence of proarrhythmia with any treatment during the study although dihydroartemisinin-piperaquine, artesunate-amodiaquine and artemether-lumefantrine significantly prolonged QTc." | ( Beavogui, AH; Borghini-Fuhrer, I; Djimdé, AA; Duparc, S; Felices, M; Funck-Brentano, C; Khan, Y; Ouedraogo, JB; Ouologuem, N; Sagara, I; Sirima, SB; Soulama, I; Voiriot, P, 2019) |
| "When amiodarone is used to treat atrial arrhythmia, the ventricular rate may accelerate, which can cause patients with borderline heart failure to develop acute heart failure or further deterioration of acute heart failure." | ( Chen, H; Jiang, W; Lin, W; Pan, B; Wang, Y; Ye, F, 2019) |
| "Patients afflicted with arrhythmia depend on antiarrhythmic medication or invasive therapy, such as pacemaker implantation." | ( Burczyk, MS; Burkhalter, MD; Cui, Y; Donow, C; Grisanti, LA; Hoffmann, C; Kauk, M; Kühl, M; Kustermann, M; Laue, S; Matysik, S; Moretti, A; Philipp, M; Raad, F; Rothe, M; Tena, TC; Tilley, DG; Wess, J; Zimmermann, WH, 2019) |
| "Severe arrhythmias-such as ventricular arrhythmias-can be fatal, but treatment options are limited." | ( Bai, K; Chen, Y; He, J; Hong, B; Huang, W; Le, Q, 2019) |
| "Surprisingly, despite the absence of arrhythmias at basal condition, we demonstrated, by in vivo and ex vivo approaches, that dexamethasone-treated rats are more susceptible to develop harmful forms of ventricular arrhythmias when challenged with pharmacological drugs or burst pacing-induced arrhythmias." | ( Araújo, JEDS; Barreto, AS; Dantas, CO; Dos Santos, RV; Lauton-Santos, S; Macedo, FN; Mesquita, TRR; Miguel-Dos-Santos, R; Quintans-Júnior, LJ; Rabelo, TK; Santana-Filho, VJ; Santos, MRVD; Silva-Filha, E; Souza, DS; Vasconcelos, CML; Zhang, R, 2020) |
| "There was no record of severe arrhythmias during the first 6 months of treatment." | ( Ciobanu, A; Gheorghe, ACD; Gheorghe, GS; Hodorogea, AS; Jinga, V; Nanea, IT; Radavoi, GD, 2020) |
| "Besides its well-known activity on arrhythmias, its usefulness in the treatment of myotonia, myotonic dystrophy and amyotrophic lateral sclerosis is now widely recognized." | ( Carocci, A; Catalano, A; Franchini, C, 2021) |
| "Also, no malignant ventricular arrhythmia or death secondary to ventricular arrhythmia occurred during the treatment in both groups." | ( Bilge, AR; Çetin, N; Gündüz, R; Özdemir, İH; Özen, MB; Özlek, B, 2021) |
| "Before radiation therapy, asymptomatic arrhythmias were detected in 43 (89,6%) patients." | ( Fedorets, VN; Kozlov, KL; Krasylnikova, LA; Vologdina, IV; Zhabina, RM, 2020) |
| "Eighty-four cases of ventricular arrhythmia-induced shock and ROSC (return of spontaneous circulation) were divided into the prior amiodarone or β-blockers use group (Aβ group, n = 27) and the non-amiodarone and non-β-blockers use group (non-Aβ group; n = 57) based on treatment before the onset of those arrhythmias." | ( Nagao, K; Tachibana, E; Ueki, Y; Yamasaki, M; Yokoyama, M; Yonemoto, N; Yoshie, K, 2021) |
| "EMPA treatment reduced ventricular arrhythmia vulnerability and mitigated contractile dysfunction in the global I/R model while improving calcium cycling and mitochondrial redox by SGLT2-independent mechanisms." | ( Azam, MA; Chakraborty, P; Du, B; Ha, ACT; Lai, PFH; Massé, S; Nanthakumar, K; Si, D, 2021) |
| "Interestingly, a decrease in arrhythmias and instabilities was observed in polytherapy relative to monotherapy, in concordance with published clinical trials." | ( Charrez, B; Charwat, V; Edwards, AG; Finsberg, H; Healy, KE; Miller, EW; Siemons, B, 2021) |
| "Treatment of cardiac arrhythmia remains challenging due to severe side effects of common anti-arrhythmic drugs." | ( Arduino, DM; Dreizehnter, L; Feng, M; Fischbach, S; Gudermann, T; Gutenthaler, SM; Moretti, A; Perocchi, F; Sander, P; Schredelseker, J; Schweitzer, MK; Wilting, F, 2021) |
| "Cardiac arrhythmias and the deterioration of osteoporosis are the most frequently documented side-effects of LT4 therapy." | ( Essack, M; Gluvic, Z; Gojobori, T; Isenovic, ER; Obradovic, M; Pitt, SJ; Samardzic, V; Soskic, S; Stewart, AJ, 2021) |
| "The treatment of cardiac arrhythmias in patients who take drugs of abuse may be specialized and will require an understanding of the unique underlying mechanisms and necessitates a multidisciplinary approach." | ( Ahmad, J; Awwab, H; Bhuiyan, MS; Dominic, P; Goeders, NE; Gopinathannair, R; Kevil, CG; Murnane, KS; Olshansky, B; Patterson, JC; Sandau, KE, 2022) |
| "The frequency and severity of the arrhythmia had a strong temporal relationship with the administration of cisplatin, that made it likely that cisplatin was responsible for the cardiotoxicity observed." | ( Dai, S; Fu, SY; Guo, FZ; Hu, HY; Huang, Y; Liu, JW; Luo, F, 2022) |
| "No data exist on comparative risk of cardiac arrhythmias among 3 Medication-Assisted Therapy (MAT) medications in patients with opioid use disorder." | ( Digbeu, B; Kuo, YF; Priyadarshni, S; Raji, MA; Yu, X, 2022) |
| "Variables recorded included heart rate, arrhythmias and complexity, total procedure time and administration of antiarrhythmic treatment, vasopressors, positive chronotropes, or fluid boluses." | ( Borgeat, K; Gomart, S; Hezzell, MJ; MacFarlane, P; Payne, JR, 2022) |
| "Prior ventricular arrhythmias and right ventricular LGE were independent predictors of appropriate therapy." | ( Akdim, F; Bakker, ALM; Balt, JC; Grutters, JC; Mathijssen, H; Post, MC; van Es, HW; Veltkamp, M, 2022) |
| "According to the past reports, similar arrhythmias have occurred after administration of epinephrine in the head and neck." | ( Kawamoto, Y; Kishimoto, S; Minamide, A; Niwa, H; Oda, W; Tooyama, M; Usami, N, 2022) |
| "Recently, unexplained ventricular arrhythmias (VAs) with next-generation BTKi-therapy have been reported." | ( Addison, D; Awan, F; Azali, L; Bhat, SA; Byrd, JC; Chen, ST; Gambril, J; Grever, M; Kalathoor, S; Kittai, A; Palettas, M; Rogers, KA; Rosen, L; Ruz, P; Wiczer, TE; Woyach, J; Zhao, Q, 2022) |
| "Intramural ventricular arrhythmias are challenging to treat." | ( Creed, E; Fernandes, GC; Hack, B; Hanley, A; Hucker, W; Jung, K; Lee, K; Nguyen, T, 2023) |
| "Fifteen had history of arrhythmias and two had a pacemaker; 64% started cannabis before or during chemotherapy and 18% had no chemotherapy." | ( Laish-Farkash, A; Moisa, N; Vasilenko, L; Vorobiof, D, 2023) |